At AACR, Cyclacel is introducing a second-generation CDK product candidate, which is currently in investigational new drug [IND]-directed development. The undisclosed molecule is a second generation oral CDK inhibitor with increased potency. Three abstracts related to both seliciclib and the second-generation compound are scheduled for presentation at AACR.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.